HMC
BNTX icon

Harvard Management Company’s BioNTech BNTX Stock Holding History

Harvard Management Company’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-31,869
Closed -$2.13M – 25
2020
Q2 		$2.13M Buy
+31,869
New +$1.59M 0.18% 19

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Harvard Management Company's BNTX Position: Q3 2020 in Review

Harvard Management Company sold out of BioNTech (BNTX) in Q3 2020, closing a stake of 31,869 shares — an estimated $2.13M sold.

Harvard Management Company first reported a position in BNTX in Q2 2020 and held it in 1 quarter. The position peaked at $2.13M in Q2 2020. 147 funds tracked by Wall St. Rank hold BNTX as of Q3 2020.

  • Harvard Management Company reported no remaining BioNTech position as of Q3 2020 after selling out during the quarter.
  • Harvard Management Company sold 31,869 BioNTech shares in Q3 2020, an estimated $2.13M.
  • Harvard Management Company first reported a position in BioNTech in Q2 2020 and held it in 1 quarter.
  • Harvard Management Company's BioNTech position peaked at $2.13M in Q2 2020.
  • 147 funds tracked by Wall St. Rank held BioNTech as of Q3 2020.

Based on Harvard Management Company's 13F filing for Q3 2020, filed 13 Nov 2020.